315 related articles for article (PubMed ID: 12881704)
1. Rescue of mutant p53 transcription function by ellipticine.
Peng Y; Li C; Chen L; Sebti S; Chen J
Oncogene; 2003 Jul; 22(29):4478-87. PubMed ID: 12881704
[TBL] [Abstract][Full Text] [Related]
2. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
3. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
4. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound.
Sun Y; Bian J; Wang Y; Jacobs C
Oncogene; 1997 Jan; 14(4):385-93. PubMed ID: 9053835
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.
Sugikawa E; Hosoi T; Yazaki N; Gamanuma M; Nakanishi N; Ohashi M
Anticancer Res; 1999; 19(4B):3099-108. PubMed ID: 10652599
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
7. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
Wang W; Takimoto R; Rastinejad F; El-Deiry WS
Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
[TBL] [Abstract][Full Text] [Related]
9. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
10. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
Kong XT; Gao H; Stanbridge EJ
J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo.
Ohtani S; Kagawa S; Tango Y; Umeoka T; Tokunaga N; Tsunemitsu Y; Roth JA; Taya Y; Tanaka N; Fujiwara T
Mol Cancer Ther; 2004 Jan; 3(1):93-100. PubMed ID: 14749479
[TBL] [Abstract][Full Text] [Related]
13. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
[TBL] [Abstract][Full Text] [Related]
14. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.
Takimoto R; Wang W; Dicker DT; Rastinejad F; Lyssikatos J; el-Deiry WS
Cancer Biol Ther; 2002; 1(1):47-55. PubMed ID: 12174820
[TBL] [Abstract][Full Text] [Related]
15. Increased apoptosis induction by 121F mutant p53.
Saller E; Tom E; Brunori M; Otter M; Estreicher A; Mack DH; Iggo R
EMBO J; 1999 Aug; 18(16):4424-37. PubMed ID: 10449408
[TBL] [Abstract][Full Text] [Related]
16. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.
Roth J; Koch P; Contente A; Dobbelstein M
Oncogene; 2000 Mar; 19(14):1834-42. PubMed ID: 10777217
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the GADD45 response to ionizing radiation in WI-L2-NS cells, a p53 mutant cell line.
Carrier F; Bae I; Smith ML; Ayers DM; Fornace AJ
Mutat Res; 1996 Jun; 352(1-2):79-86. PubMed ID: 8676920
[TBL] [Abstract][Full Text] [Related]
18. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2.
Blaydes JP; Wynford-Thomas D
Oncogene; 1998 Jun; 16(25):3317-22. PubMed ID: 9681831
[TBL] [Abstract][Full Text] [Related]
19. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
[TBL] [Abstract][Full Text] [Related]
20. Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage.
Savorani C; Manfé V; Biskup E; Gniadecki R
Leuk Lymphoma; 2015 Mar; 56(3):739-47. PubMed ID: 24898668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
